TERN Quote, Financials, Valuation and Earnings

Amgen has a net margin of -- compared to Terns Pharmaceuticals's net margin of 6.9%. Terns Pharmaceuticals's return on equity of -- beat Amgen's return on equity of 66.87%.

Terns Pharmaceuticals has a consensus price target of $19.06, signalling upside risk potential of 552.83%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could grow by 2.93%. Given that Terns Pharmaceuticals has higher upside potential than Amgen, analysts believe Terns Pharmaceuticals is more attractive than Amgen.

Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 2.97% to investors and pays a quarterly dividend of $2.38 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

Terns Pharmaceuticals quarterly revenues are --, which are smaller than Amgen quarterly revenues of $9.1B. Terns Pharmaceuticals's net income of -$21.8M is lower than Amgen's net income of $627M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Amgen's PE ratio is 40.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 4.96x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Terns Pharmaceuticals's net margin of 32.59%. Terns Pharmaceuticals's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Terns Pharmaceuticals has a consensus price target of $19.06, signalling upside risk potential of 552.83%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.85%. Given that Terns Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Terns Pharmaceuticals is more attractive than Eli Lilly and.

Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Terns Pharmaceuticals quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Terns Pharmaceuticals's net income of -$21.8M is lower than Eli Lilly and's net income of $4.4B. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 70.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 16.51x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Terns Pharmaceuticals's net margin of 2.31%. Terns Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.91%.

Terns Pharmaceuticals has a consensus price target of $19.06, signalling upside risk potential of 552.83%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 23.99%. Given that Terns Pharmaceuticals has higher upside potential than Pfizer, analysts believe Terns Pharmaceuticals is more attractive than Pfizer.

Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.7% to investors and pays a quarterly dividend of $0.43 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Terns Pharmaceuticals quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Terns Pharmaceuticals's net income of -$21.8M is lower than Pfizer's net income of $410M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 2.26x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Terns Pharmaceuticals's net margin of --. Terns Pharmaceuticals's return on equity of -- beat Viking Therapeutics's return on equity of --.

Terns Pharmaceuticals has a consensus price target of $19.06, signalling upside risk potential of 552.83%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 287.11%. Given that Terns Pharmaceuticals has higher upside potential than Viking Therapeutics, analysts believe Terns Pharmaceuticals is more attractive than Viking Therapeutics.

Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Terns Pharmaceuticals quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Terns Pharmaceuticals's net income of -$21.8M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.